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Aims Remodelling of gap junctions, involving reduction of total gap junction quantity and down-
regulation of connexin43 (Cx43), contributes to the arrhythmic substrate in congestive heart failure.
However, little is known of the underlying mechanisms. Recent studies from in vitro systems suggest
that the connexin-interacting protein zonula occludens-1 (ZO-1) is a potential mediator of gap junction
remodelling. We therefore examined the hypothesis that ZO-1 contributes to reduced expression of
Cx43 gap junctions in congestive heart failure.
Methods and results Left ventricular myocardium from healthy control human hearts (n ¼ 5) was com-
pared with that of explanted hearts from transplant patients with end-stage congestive heart failure
due to idiopathic dilated cardiomyopathy (DCM; n ¼ 5) or ischaemic cardiomyopathy (ICM; n ¼ 5).
Immunoconfocal and immunoelectron microscopy showed that ZO-1 is speciﬁcally localized to the inter-
calated disc of cardiomyocytes in control and failing ventricles. ZO-1 protein levels were signiﬁcantly
increased in both DCM and ICM (P ¼ 0.0025), showing a signiﬁcant, negative correlation to Cx43
levels (P ¼ 0.0029). There was, however, no signiﬁcant alteration of ZO-1 mRNA (P ¼ 0.537). Double
immunolabelling demonstrated that a proportion of ZO-1 label is co-localized with Cx43, and that
co-localization of Cx43 with ZO-1 is signiﬁcantly increased in the failing ventricle (P ¼ 0.003).
Interaction between the two proteins was conﬁrmed by co-immunoprecipitation. The proportion of
Cx43 that co-immunoprecipitates with ZO-1 was signiﬁcantly increased in the failing heart.
Conclusion Our ﬁndings suggest that ZO-1, by interacting with Cx43, plays a role in the down-regulation
and decreased size of Cx43 gap junctions in congestive heart failure.
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1. Introduction
Gap junctions, clusters of cell-to-cell channels composed of
connexins, mediate the orderly spread of electrical exci-
tation throughout the heart.1 Experimental evidence from
transgenic murine models,2–5 combined with ﬁndings from
the diseased human heart,6–12 indicate that altered ventri-
cular gap junction organization and connexin expression
are key contributors to rhythm disturbances and contractile
dysfunction. These alterations, referred to as gap junction
remodelling, may take the form of structural modiﬁcations,
involving disturbances in the distribution of gap junctions
and/or changes in the amount or type of connexin(s)
expressed.1,13 In patients with end-stage congestive heart
failure [due to ischaemic cardiomyopathy (ICM) or idiopathic
dilated cardiomyopathy (DCM)], the most prominent fea-
tures of remodelling involve down-regulation of connexin43
(Cx43), reduction in gap junction plaque size and increased
heterogeneity of gap junction distribution.6,8,10–12 While
some mediators of Cx43 gap junction remodelling have
been explored,14,15 our knowledge of the underlying mech-
anisms in human heart failure remains limited.
Recent evidence from various cell types has highlighted a
role for connexin-interacting proteins,16 and in particular,
the membrane-associated guanylate kinase, zonula
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and size of Cx43 gap junctions.17–19 The interaction between
ZO-1 and Cx43 is mediated through the second PDZ domain
of ZO-1 and a PDZ-binding motif at the extreme carboxy ter-
minus of Cx43.20,21 ZO-1 was originally identiﬁed as a tight
junction protein, where it functions to tether transmem-
brane proteins to the actin cytoskeleton.22,23 Initially, it
was assumed that ZO-1 forms a link between Cx43 and the
cytoskeleton, thereby stabilizing gap junctions at the
plasma membrane,21 but recent data suggest an additional,
more dynamic role. In particular, inhibition of Cx43/ZO-1
interaction in a HeLa cell model results in the formation of
abnormally large gap junctions, an effect rescued by restor-
ation of the interaction.18 These ﬁndings raise the possibility
that the reduction in ventricular Cx43 gap junction content
in human congestive heart failure could be mediated, at
least in part, via altered Cx43/ZO-1 interaction.
Accordingly, in this study, we set out to explore the
hypothesis that ZO-1 plays a role in disease-related gap
junction remodelling in the human heart. We show that
ZO-1 is localized at the intercalated disc of human ventricu-
lar myocytes where it interacts with Cx43, and that the pro-
portion of Cx43 that interacts with ZO-1 is signiﬁcantly
enhanced in the left ventricle of patients with congestive
heart failure. A novel feature of our study is separate analy-
sis of this interaction in the fraction of Cx43 within gap-
junctional plaques (junctional fraction) and that elsewhere
in the cell (non-junctional fraction).
2. Methods
2.1 Human heart samples
The study was conducted on explanted hearts of patients
with ICM (n ¼ 5) or DCM (n ¼ 5) undergoing orthotopic
cardiac transplantation at the Royal Brompton and Hareﬁeld
NHS Trust Hospitals (Table 1). Samples of human left ventri-
cles (encompassing the full thickness of the free wall) were
snap-frozen in liquid nitrogen. As controls, tissues from ﬁve
normal hearts initially harvested for use as transplantation
donor organs, but rejected for technical reasons, were
used. The study was approved by the Brompton, Hareﬁeld
and NHLI Research Ethics Committee (#04–101 and #01–
194). The investigation conforms with the principles out-
lined in the Declaration of Helsinki.24
2.2 Immunoconfocal and electron microscopy
Immunoconfocal microscopy was conducted on cryosections
of tissue that was directly frozen, without prior aldehyde
ﬁxation.6 For immunoelectron microscopy, tissue was pro-
cessed by low denaturation procedures and thin sections
were immunogold labelled.25,26 Primary antibodies used
were anti-Cx43 (Chemicon International Ltd), anti-ZO-1
(Zymed, 40–2200), and anti-CD31 (Sigma). For details of
antibody characterization and speciﬁcity, see Supplemen-
tary material.
2.3 Quantiﬁcation of protein levels
by western blotting
Western blotting and quantiﬁcation were carried out as
described previously8 using anti-ZO-1 (Zymed, 61–7300) or
anti-Cx43 (Sigma) antibodies.
2.4 Quantiﬁcation of mRNA levels by northern
blotting
RNA extraction and northern blotting were carried out as
previously described.27 A cDNA encompassing nucleotides
3394–5548 of the human ZO-1 coding sequence was gene-
rated by PCR from human DNA, and cloned into pGEMw-T
Table 1 Patient details
Heart no. Age (years) Sex (M/F) Cardiac disease Other diagnoses Echocardiography NYHA class
LVEDD (mm) FS (%)
Controls
1 22 F None ICH
2 25 F None ICH
3 48 F None
4 19 F None CF (dominoa)
5 52 M None Head trauma
Idiopathic dilated cardiomyopathy
6 41 M DCM 74 5.4 4
7 52 M DCM 50 16 4
8 38 M DCM 100 4 4
9 46 F DCM NIDDM 76.8 19.6 4
10 65 F DCM 4
Ischemic cardiomyopathy
11 50 M ICM, 3VD 80 14.4 4
12 61 M ICM, 3VD NIDDM 74.2 15.4 4
13 54 M ICM 65 13.8 4
14 52 M ICM Asthma 47 19 4
15 46 M ICM Hodgkin’s 43 ,30b 4
aDomino ¼ patient receiving dual heart/lung transplant (for lung disease), the explanted healthy heart being intended for transplantation in another
patient; bPrecise ﬁgure not available. NIDDM, non-insulin dependent diabetes mellitus; LVEDD, left ventricle end-diastolic diameter (normal range: 37–
56); FS, fraction shortening (normal range: 34–44); ICH, intra-cranial haemorrhage; CF, cystic ﬁbrosis; 3VD; triple valve disease. Some patients were used
in a previous study.8
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Easy vector (Promega). Following release from the vector,
the probe was used at a concentration of 2.5 ng ml21 after
random primer labelling with 32P dCTP. Northern blots
were quantiﬁed following normalization against methylene
blue stained 18S RNA.8
2.5 Quantitative analysis of immunolabelled Cx43
and ZO-1 by confocal microscopy
Quantiﬁcation of ZO-1 and Cx43 immunolabelling was per-
formed using a Leica TCS 4D confocal microscope and PC
ImageTM software (Foster Findlay Associates).6 Blind
measurements were taken of the ﬂuorescent label in 10 indi-
vidual en face intercalated discs per section, selected by
random scanning across the tissue. Serial optical sections
(0.5 mm intervals) were acquired at 63 magniﬁcation,
with a setting of zoom4 and a 512  512-pixel image size,
yielding a pixel size of 0.08 mm. Using PC ImageTM software,
individual complete discs were outlined by hand for separ-
ate quantiﬁcation and thresholds for detection on a
255-point grey scale adjusted to reduce any background
cell outlines. A pixel-by-pixel analysis was used to assess
label for Cx43, ZO-1, and both Cx43 and ZO-1 (co-localized)
label.
2.6 Extraction of non-junctional
and junctional proteins
To enable separate analysis of Cx43 within gap junctions (the
‘junctional’ fraction) and that elsewhere in the cell (the
‘non-junctional’ fraction), Triton X-100 (TX-100) extraction
was performed. The non-junctional fraction, comprising
cytoplasmic Cx43 en route to the plasma membrane, Cx43
in the plasma membrane as undocked connexons, and
Cx43 en route to degradation, is soluble in TX-100,
whereas the Cx43 in the docked connexons of gap-junctional
plaques is not. Samples of frozen left ventricle were pulver-
ized,8 then homogenized by sonication in immunoprecipita-
tion (IP) buffer (10 ml mg21 frozen tissue: 25 mM Tris, pH7.4;
150 mM NaCl; 1/250 mammalian tissue extract protease
inhibitors [Sigma]; 1% TX-100). The samples were incubated
on ice for 30 min, with vortexing every 5 min, and then cen-
trifuged (15 000 rpm, 30 min, 4oC). Non-junctional proteins
in the supernatant were collected. Junctional proteins in
the pellet were re-suspended in an equal volume (i.e.
10 ml mg21 tissue) of IP buffer containing 4 M urea.
Samples were sonicated, incubated at room temperature
for 30 min with vortexing, centrifuged (15 000 rpm,
30 min, 48C), and junctional proteins collected in the super-
natant. Urea (8 M) separates the component membranes of
gap junctions,28 thereby undocking connexons and making
them soluble in TX-100 for processing. We have checked
the validity of using 4 M urea to extract junctional connexins
from non-puriﬁed gap-junctional membranes by solubilizing
the ﬁnal pellet with 20% SDS. Negligible connexin levels
were detectable in this fraction by western blot.
Prior to IP, junctional proteins were desalted using
Bio-Gelw P-6 DG desalting gel (Bio-Rad) and IP buffer in
Zeba spin columns (Pierce).
2.7 Cross-linking
Proteins were extracted in IP buffer containing PBS instead
of Tris. Prior to the ﬁrst centrifugation, an equal volume of
0.2 M ethanolamine, pH 8, containing 0.5 mM dimethyl-3-
30-dithiobispropionimidate (DTBP; Sigma) was added.
Following incubation for 30 min at room temperature, an
equal volume of 50 mM Tris, pH 7.4, was added to quench
the reaction. Non-junctional and junctional protein extrac-
tion was then carried out as described above.
2.8 Co-immunoprecipitation
Protein samples were incubated with 2.5 mg of anti-ZO-1
(Zymed, 61–7300) or anti-Cx43 (Sigma) antibody overnight
at 48C with rotation, followed by 1 h at 48C with 25 ml
protein-A coated agarose beads (Pierce). Beads were
washed with ice-cold IP buffer by centrifugation (2 min,
2500 rpm)/re-suspension. Bound proteins were desorbed by
re-suspension in 20% SDS, containing 2.5% 2-mercaptoetha-
nol. ZO-1/Cx43 interactions were quantiﬁed by western
blotting using a polyclonal anti-Cx43 antibody (Sigma;
favoured over the monoclonal anti-Cx43 (Chemicon)
because of its higher sensitivity and ability to recognize all
phosphorylated forms of Cx43), following normalization
against Coomassie blue-stained actin. Control experiments,
in which primary antibodies were omitted, excluded non-
speciﬁc interactions.
2.9 Statistical analysis
All analysis was done using GraphPad Prism 4 (GraphPad
Software Inc.). Data are expressed as mean + SEM. Statisti-
cal signiﬁcance was evaluated with ANOVA. Statistical
differences were judged signiﬁcant at P  0.05.
3. Results
3.1 Localization of ZO-1 in human ventricular
cardiomyocytes
Immunoconfocal localization of ZO-1 in longitudinal sections
of left ventricular tissue shows prominent signal which, at
ﬁrst sight, appears to outline individual myocytes, thereby
suggesting the presence of ZO-1 throughout the entire
myocyte plasma membrane (Figure 1A). However, careful
comparison with the labelling patterns obtained for the
endothelial marker, CD31, in both longitudinal and trans-
verse planes, demonstrates that the apparent lateral label-
ling of the myocytes is, in fact, attributable to capillaries
(Figures 1A–F). In longitudinal sections, CD31 highlights
capillaries running alongside the myocytes (Figure 1B);
transverse sections correspondingly show capillaries as
small, prominently labelled circular proﬁles or streaks,
with no signal of the myocytes that occupy the spaces
between (Figure 1E). ZO-1 labelling of transverse sections
showed similar small capillary proﬁles (Figure 1D), account-
ing for the apparent lateral label in longitudinal sections.
There was no label circumscribing the myocyte bodies as
would be expected if ZO-1 were present throughout the
lateral plasma membrane. Periodic large discs were
observed ﬁlled with positive ZO-1 signal occupying the
entire myocyte cross-sectional area; these represented
intercalated discs (Figure 1D). As conﬁrmed by the merged
images (Figures 1C and F), these observations indicate
that, in human ventricular myocytes, ZO-1 is conﬁned to
the intercalated disc plasma membranes. This pattern of
ZO-1 localization was not altered in the failing heart.
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Immunogold labelling at the higher resolution afforded by
electron microscopy conﬁrmed and extended these
conclusions. ZO-1 gold label was localized speciﬁcally to
intercalated disc membranes; no label was apparent at the
Figure 1 Localization of ZO-1 in human left ventricular myocardium. Immunoconfocal microscopy comparing labelling patterns for ZO-1 (red) and CD31 (green)
as seen in double-labelled longitudinal (A–C) and transverse (D–F) sections. CD31 labelling identiﬁes capillaries that run alongside the myocytes. When the
images are merged, the ZO-1 labelling pattern can be seen to arise in part from capillaries (examples ringed by continuous lines) and from speciﬁc staining
of myocyte intercalated discs (examples ringed by dashed lines). Merging the images (C and F) conﬁrms that there is no detectable ZO-1 label in the lateral
plasma membranes of the myocytes. In the myocytes, only the intercalated discs (d) contain red ZO-1 label. Sale bar ¼ 50 mm.
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lateral plasma membrane or membranes of intracellular
organelles (Figure 2). Within the intercalated disc, ZO-1
label was observed both in association with gap junctions,
particularly at the junctional edge, and in intervening seg-
ments of disc membrane.
3.2 ZO-1 expression levels
To determine whether the expression levels of ZO-1 differed
between control and failing ventricles, western and north-
ern blot analyses were conducted. ZO-1 was detected by
western blot as a prominent band migrating at 225 kDa
(Figure 3A). Visual examination indicated increased levels
of ZO-1 in both DCM and ICM vs. controls, which was con-
ﬁrmed by densitometric analysis following normalization
against Coomassie blue-stained actin (P ¼ 0.0025).
Western blot analyses of Cx43 protein levels accorded with
previous studies showing down-regulation in the failing heart
(P, 0.0001; Figure 3A and B). Plotting these data against
ZO-1 protein levels revealed a signiﬁcant negative correlation
between Cx43 and ZO-1 (Figure 3C), i.e. low Cx43 levels cor-
respond to high levels of ZO-1 (P ¼ 0.0029; r2 ¼ 0.51).
ZO-1 mRNA was detected by northern blot as a single
8 kb band after 3–5 h exposure (Figure 4). Densitometric
analysis following normalization against methylene blue
stained 18S RNA showed no signiﬁcant difference between
transcript levels in control and failing hearts (P ¼ 0.537).
3.4 Co-localization of ZO-1 and Cx43 at the
intercalated disc
To assess the possibility of interaction between ZO-1 and
Cx43, quantitative double-label immunoconfocal microscopy
was carried out in serial confocal reconstructions of en face
intercalated discs, and the extent of co-localization
determined.
Cx43 labelling revealed the typical pattern comprising
large gap junctions at the periphery of the disc enclosing
smaller junctions in the interior zone (Figure 5A).6,29,30
ZO-1 label was apparent across the entire face of the disc
in both control and failing hearts. Double-labelled sections
revealed substantial areas with Cx43 or ZO-1 signal only.
However, a small proportion of co-localized signal was con-
sistently apparent, indicating the existence of a pool of
Cx43 situated where it could potentially interact with ZO-1.
Quantitative analysis demonstrated that Cx43 label per
unit area of disc was reduced in failing ventricles compared
with controls (P ¼ 0.004; Figure 5B). In contrast, ZO-1 label
was increased in failing ventricles compared with controls
Figure 3 Quantiﬁcation of ZO-1 in human left ventricular tissue. (A) Typical
western blots for ZO-1 and Cx43 and parallel Coomassie-blue staining for
actin. Patient numbers (Table 1) and sample categories are indicated. (B)
ZO-1 and Cx43 were quantiﬁed following normalization with the densito-
metric values of actin. ZO-1 is signiﬁcantly elevated compared with controls
(100+11.40%) in DCM (175.3+11.58%) and ICM (148.7+12.62%; P ¼
0.0025). Quantiﬁcation of Cx43 immunoblots conﬁrmed signiﬁcant down-
regulation in failing samples (DCM ¼ 65.85+4.64; ICM ¼ 53.40+1.69%)
compared with controls (100+5.17%; P , 0.0001). (C) There is a signiﬁcant,
negative correlation between Cx43 and ZO-1 protein levels (P ¼ 0.0029; r2 ¼
0.51). ***P , 0.0001 **P , 0.01; *P , 0.05 vs. controls.
Figure 2 Thin-section electron micrograph of Lowicryl-embedded tissue immunogold labelled for ZO-1. Gold label occurs speciﬁcally at the intercalated discs,
notably at the edges of gap junctions (GJ; arrowheads), as well as in non-gap-junctional membranes (arrows). Sale bar ¼ 100 nm.
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(P ¼ 0.031; Figure 5B). The proportion of Cx43 signal
co-localizing with ZO-1 was increased in failing ventricles
compared with controls (P ¼ 0.003; Figure 5C). The pro-
portion of ZO-1 signal co-localizing with Cx43 did not
differ between failing and control hearts owing to the
overall increase in ZO-1 observed in the former (P ¼ 0.155).
3.5 Co-immunoprecipitation of Cx43 and ZO-1
Increased co-localization of Cx43 with ZO-1 raises the possi-
bility of, but does not strictly demonstrate, an increased
Cx43/ZO-1 interaction in the failing heart. To determine
the extent of any interaction, co-immunoprecipitation
experiments were carried out.
Using anti-ZO-1 or anti-Cx43 antibodies, ZO-1 and Cx43
were co-immunoprecipitated from human ventricular
samples (Figure 6). Owing to the limited availability of
human samples, low levels of ZO-1/Cx43 interaction and
high sensitivity of the anti-Cx43 antibody (Sigma) in
western blot analysis, co-immunoprecipitation was quanti-
ﬁed by western blotting for Cx43 following IP with
anti-ZO-1 antibody (Figure 7A). Remnants of the IgG heavy
chain from the antibody used for co-immunoprecipitation
are visible, but are readily distinguishable from Cx43
signal (Figure 7A). Densitometric analyses of Cx43 brought
down with ZO-1 following normalization against total actin
(Figure 7B) indicated that in both non-junctional and junc-
tional fractions, slightly more Cx43 interacts with ZO-1 in
the failing ventricles compared with controls, although
this difference between absolute levels did not attain
statistical signiﬁcance (P ¼ 0.397 and P ¼ 0.209,
Figure 6 Co-immunoprecipitation of Cx43 and ZO-1. Using anti-ZO-1 or
anti-Cx43 antibodies, ZO-1 and Cx43 were co-immunoprecipitated from human
heart samples.
Figure 5 Co-localization of Cx43 and ZO-1 at the intercalated disc. (A) Example of an en-face viewed intercalated disc immunolabelled for Cx43 and ZO-1.
Although Cx43 is seen predominantly as large gap junctions at the disc periphery whereas ZO-1 is spread evenly across the disc, a small fraction of each
signal overlaps (yellow), indicating co-localization. Sale bar ¼10 mm. (B and C) Quantiﬁcation of Cx43 and/or ZO-1 immunolabel at the intercalated disc. PC
ImageTM software uses the relative grayscale intensity to select pixels speciﬁc for immunolabelling to determine a total pixel count. (B) The proportion of
the disc labelled for Cx43 is reduced compared with controls (C; 100+7.52%) in DCM (74.17+2.58%) and ICM (73.44+3.91%; P ¼ 0.004). ZO-1 label is increased
compared with controls (C; 100+11.61%) in DCM (153.1+13.21%) and ICM (134.6+10.23%; P ¼ 0.031). (C) Cx43 co-localization with ZO-1 is increased com-
pared with controls (C; 100+6.91%) in DCM (161.8+ 9.06%) and ICM (144.6+11.30%; P ¼ 0.003). **P , 0.01; *P, 0.05 vs. controls. Only P-values ,0.05 are
shown.
Figure 4 Northern analysis of ZO-1 mRNA expression. (A and B) Typical
hybridizations with a probe for ZO-1 (upper panels) and corresponding
methylene blue staining (lower panels). Patient numbers (Table 1), sample
categories, and the migration of the 28S and/or 18S rRNA are indicated.
(C) ZO-1 mRNA levels in failing hearts expressed relative to control samples
following normalization with 18S mRNA. No signiﬁcant differences are appar-
ent between failing and control hearts (P ¼ 0.537).
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respectively; Figure 7B). However, as Cx43 is down-
regulated in the failing left ventricle (Figure 3) and this
occurs in both non-junctional and junctional fractions
(data not shown; P ¼ 0.053 and P ¼ 0.023, respectively),
Cx43 co-immunoprecipitation with ZO-1 is more meaning-
fully quantiﬁed relative to Cx43 levels in each sample
(Figure 7C). This demonstrated that the proportion of
Cx43 that interacts with ZO-1 is signiﬁcantly increased in
the failing ventricle compared with controls in both non-
junctional and junctional fractions (P ¼ 0.01 and P ¼ 0.01,
respectively).
Tissue was treated with the reversible cross-linking
reagent DTBP to examine the Cx43/ZO-1 association in the
in vivo setting, and to establish whether the interaction
was altered during protein extraction. Densitometric analy-
sis of western blots indicated that cross-linking did not alter
the amount of Cx43 co-immunoprecipitated with ZO-1 in the
non-junctional or junctional fractions from control (P ¼
0.759 and P ¼ 0.246, respectively), DCM (P ¼ 0.363 and
P ¼ 0.629, respectively), or ICM (P ¼ 0.304 and P ¼ 0.111,
respectively) samples (data not shown).
4. Discussion
Evidence that gap junction remodelling and altered con-
nexin expression are contributory factors in the develop-
ment of arrhythmia in human heart disease is now
compelling. It is well established that heterogeneous
reduction in Cx43 expression and disordering in gap
junction distribution occur in deﬁned forms of ventricular
disease and correlate with electrophysiologically identiﬁed
arrhythmic changes and contractile dysfunction in animal
models.1–13,31,32 Although disease-related down-regulation
of Cx43 involves reduction in gap junction size,6,12 the
cellular mechanisms responsible for this remodelling
remain largely unexplored. This study sheds new light on
this aspect of human congestive heart failure by demon-
strating that (i) ZO-1 is speciﬁcally localized at the interca-
lated disc of human cardiac myocytes, (ii) a pool of this ZO-1
is closely associated with gap junctions and interacts with
Cx43, (iii) ZO-1 is up-regulated in parallel with the
reduced expression of Cx43 in heart failure, and (iv) this
change is accompanied by an increase in the proportion of
Cx43 interacting with ZO-1.
Several previous studies have claimed that ZO-1 is present
at both the intercalated discs and lateral plasma membrane
of mammalian cardiomyocytes.33–35 By comparing the distri-
bution pattern of ZO-1 with the endothelial marker, CD31, in
transverse and longitudinal sections, we demonstrate
unequivocally here that ZO-1 is conﬁned to the intercalated
disc plasma membranes of human ventricular cardiomyo-
cytes, as also concluded in studies on rat myocytes.21,36–39
The apparent lateral labelling previously described arises
from labelling of endothelial cell plasma membranes of
the numerous capillaries running adjacent to and parallel
with myocytes in longitudinal section view. We found that
the restriction of ZO-1 to the intercalated disc did not
alter in the failing left ventricle, but in contrast to a
recent report,40 the overall level of ZO-1 protein expression
was increased. ZO-1 transcript levels, however, remained
unchanged, indicating post-transcriptional control of ZO-1
levels, for example through increased half-life or increased
efﬁciency of translation.
Immunoconfocal analysis shows that although the
majority of Cx43 in the human ventricle is not associated
with ZO-1, a small but signiﬁcant pool of each protein
co-localizes with the other. While previous studies have
reported low levels of co-localization between Cx43 and
Figure 7 (A) Typical western blots for Cx43 co-immunoprecipitated with ZO-1 (upper panel), parallel Coomassie-blue stained actin (middle panel) and Cx43 in
the starting fraction (lower panel). Patient heart numbers (Table 1) and sample categories are indicated and the migration of the IgG heavy chain and Cx43 are
shown. (B) Cx43 co-immunoprecipitation with ZO-1, following normalization to total actin, was quantiﬁed relative to the controls. In both non-junctional and
junctional fractions slightly more Cx43 was brought down by ZO-1 in DCM (117.5+ 17.73 and 118.7+ 15.37%, respectively) and ICM (128.8+11.72 and
134.8+6.30%, respectively) relative to controls (100+13.44 and 100+15.74%) but this did not attain statistical signiﬁcance (P ¼ 0.397 and P ¼ 0.209, respect-
ively). (C) Since Cx43 is down-regulated in congestive heart failure, Cx43 co-immunoprecipitated with ZO-1 was additionally quantiﬁed relative to Cx43 levels in
each sample. In both non-junctional and junctional fractions a greater proportion of Cx43 was brought down by ZO-1 in DCM (12.76+1.65 and 10.22+1.11%,
respectively) and ICM (12.76+ 1.02 and 11.54+1.25%, respectively) relative to controls (6.93+1.14 and 6.47+0.52%; P ¼ 0.011 and P ¼ 0.011, respectively).
*P , 0.05 vs. controls.
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ZO-1 in non-myocyte cell types41–43 and ratmyocytes,36,44 only
two of these studies quantiﬁed the extent of the overlap.36,44
Barker et al.36 reported that at intercalated discs of adult rat
ventricle, 15% of ZO-1 signal co-localizes with Cx43. This is
comparable to our ﬁnding of 21% in control human ventri-
cle. Our immunoelectron microscopy data conﬁrm that ZO-1
signal is associated preferentially with the edges of gap
junctions, in keeping with earlier reports.44,45
More crucial to potential regulatory mechanisms,
however, is the extent of Cx43 co-localization with ZO-1,
and whether this represents interaction between the pro-
teins. In human congestive heart failure, we show a signiﬁ-
cant increase in co-localization of Cx43 with ZO-1.
Co-immunoprecipitation analyses conﬁrmed an association
and demonstrate that, while only a small proportion of
Cx43 interacts with ZO-1, this proportion is signiﬁcantly
increased in the failing left ventricle. There was no
signiﬁcant difference in the amount of Cx43
co-immunoprecipitated with ZO-1 following cross-linking,
demonstrating that the protein extraction procedure does
not disrupt or initiate the interaction.
Our data show that the increased proportion of Cx43
interacting with ZO-1 accompanies the down-regulation of
Cx43 that has been consistently reported in human conges-
tive heart failure.1,8,10–13,31,32 Interaction of ZO-1 with
Cx43 has been previously implicated in regulation of the
size and distribution of gap junctions. In an experimental
HeLa cell system, blocking the interaction leads to the for-
mation of exceptionally large gap junctions, whose growth
is apparently unconstrained.17,18 A current hypothesis is
that ZO-1 regulates gap junction plaque size.18 The localiz-
ation of ZO-1 at the periphery of gap junction plaques44
places it in an ideal position to inhibit further recruitment
of connexons18 or to favour the removal of gap junctions
on reaching a certain size. Thus, increased interaction of
Cx43 with ZO-1—as demonstrated here—could decrease the
maximum size to which the gap junctions grow, thereby con-
tributing to reduction in the overall levels of Cx43 in the
failing heart.
Our co-immunoprecipitation experiments demonstrated,
however, that Cx43 interaction with ZO-1 was not only
detected in the junctional fraction (i.e. within gap junc-
tions), but also in the non-junctional fraction. As the non-
junctional fraction includes undocked connexons that lie
outside gap junction plaques, this might reﬂect a role for
Cx43/ZO-1 interaction at the edge of the gap junction,
i.e. at the transition between junctional and non-junctional
membrane. However, an effect at the cytoplasmic level
cannot be excluded. Binding of ZO-1 to Cx43 connexons en
route to the plasma membrane (possibly in a proportion dic-
tated by the metabolic state of the cells) could conceivably
be a signal by which gap junction size and overall quantity is
limited. Increased Cx43/ZO-1 association is a prominent
feature of some situations in which gap junctions are inter-
nalized by endocytosis, both in rat cardiac myocytes36 and
non-myocyte cell types.42 Internalization of gap junctions,
mediated via interactions with the spectrin/actin cytoskele-
ton,36,46 is a prelude to degradation, at which point any
Cx43/ZO-1 interaction may be detected in the non-
junctional as well as junctional fractions. Thus, our ﬁndings
highlight the possibility of increased ZO-1-mediated degra-
dation of Cx43 as an alternative/additional mechanism of
reduced Cx43 expression in heart failure.
In summary, Cx43 and ZO-1 protein levels are negatively
correlated in the failing human ventricle and a pool of
Cx43 interacts with ZO-1 at the intercalated discs. Our
data are consistent with the hypothesis that ZO-1, through
interacting with Cx43, is involved in decreasing gap junction
size and quantity in congestive heart failure, possibly by reg-
ulating the size of the Cx43 gap junction and/or mediating
gap junction endocytosis.
Supplementary material
Supplementary material is available at Cardiovascular
Research online.
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